Lack of PRAME Expression in Cutaneous T-Cell Lymphomas

Chau M Bui; Sumire Kitahara; Wonwoo Shon; Tatsiana Pukhalskaya; Bruce R Smoller

doi:10.3390/dermatopathology9010002

Lack of PRAME Expression in Cutaneous T-Cell Lymphomas

Dermatopathology (Basel). 2021 Dec 31;9(1):11-16. doi: 10.3390/dermatopathology9010002.

Authors

Chau M Bui¹, Sumire Kitahara¹, Wonwoo Shon¹, Tatsiana Pukhalskaya², Bruce R Smoller²

Affiliations

¹ Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
² Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.

Abstract

Cutaneous T-cell lymphomas (CTCLs) are rare tumors with no established markers that can reliably distinguish between benign and malignant lesions. Preferentially Expressed Antigen in Melanoma (PRAME) is a cancer/testis antigen that is found in many solid and hematologic malignancies. PRAME overexpression typically portends a poor prognosis and lower chemotherapeutic response. To date, no studies have established a role for PRAME in CTCL. An analysis was performed on 47 cases definitively diagnosed as CTCL: 25 cases of mycosis fungoides, 2 of Sezary syndrome, 5 of CD30+ lymphoproliferative disorder, 7 of primary cutaneous anaplastic large T-cell lymphoma, 3 of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder, 1 of subcutaneous panniculitis-like T-cell lymphoma, and 4 of angiocentric T-cell lymphoma. PRAME immunohistochemistry was completely negative in all cases. PRAME expression was not found in any CTCL subtypes, suggesting that the pathogenesis of CTCL is not mediated by PRAME. Further study is required to identify biomarkers that might aid in the diagnosis and prognostication of CTCLs.

Keywords: PRAME; cutaneous T-cell lymphoma.